BioAge is translating insights from the science of aging into new medicines

What It Covers

BioAge CEO Kristen Fortney explains how studying centenarian biology and aging pathways—including NLRP3 inflammation and exercise-mimicking compounds like apelin—drives drug discovery targeting metabolic and age-related diseases.

Key Questions Answered

• •NLRP3 Inflammasome Targeting: Chronic inflammation rises with age and drives metabolic disease, including obesity. BioAge's brain-penetrant NLRP3 inhibitors, entering clinical trials in 2025, aim to suppress neuroinflammation that disrupts appetite regulation—offering a potential intervention earlier in disease progression than current treatments address.
• •Exercise Biology as Drug Discovery: Apelin, a circulating blood factor that declines with age but surges during exercise, represents a class of "exerkines" that can be mimicked therapeutically. BioAge's Novartis partnership targets this biology to identify metabolic and neurological drug candidates modeled on exercise's proven physiological benefits.
• •Centenarian Data as Target Validation: Studying people who live past 100 in good physical and cognitive health reveals molecular differences that validate drug targets. CETP inhibitors, for example, were identified partly because centenarians carry natural loss-of-function mutations in that gene—providing human genetic proof before clinical development.
• •Sarcopenia Regulatory Gap: No FDA approval pathway currently exists for sarcopenia or frailty, despite measurable endpoints and large patient populations. Establishing this path—as the EMA and Japan are exploring given aging demographics—could unlock a significant pipeline of muscle-preserving therapies and accelerate investment in aging indications.